CORRECTION

Correction to: The efficacy and safety of menatetrenone in the management of osteoporosis: a systematic review and meta-analysis of randomized controlled trials

S. Su [1,2] · N. He [1,2] · P. Men [1] · C. Song [3] · S. Zhai [1]

Correction to: Osteoporosis International (2019) 30:1175–1186
https://doi.org/10.1007/s00198-019-04853-7

The original version of this article, published on February 7, 2019, contained a mistake.

The correct information is given below. The original article has been corrected.

Results *- Efficacy evaluations - Menatetrenone versus placebo/no additional drug:*

"In addition, analysis of **four** studies [22,24,26,38] (N=**356**) revealed a significantly greater percent increase in lumbar BMD from baseline for menatetrenone compared with placebo or no additional anti-osteoporotic drug (MD=**2.02%**, 95% CI **1.05** to **2.99%**, P <**0.0001**) (Fig. 3 and Online Resource 3)."

Table 1. *Characteristics of the included RCTs*
In the "Outcome" column, the Orimo 1999 study should be "9,12,13" rather than "5,9,12,13".

Correction in supplementary material

✉ S. Zhai
  zhaisuodi@163.com

1   Department of Pharmacy, Peking University Third Hospital, 49 Huayuan North Road, Haidian District, Beijing 100191, China

2   Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Science, Peking University, Beijing, China

3   Department of Orthopaedics, Peking University Third Hospital, Beijing, China

Fig. 3 Summary of results of the meta-analyses for continuous variables (only summary effect estimate of menatetrenone vs. placebo – LBMD change (%) was changed)